Polypeptide Publishes Invitation To The Annual General Meeting 2024


(MENAFN- EQS Group)

PolyPeptide Group / Key word(s): AGMEGM
PolyPeptide publishes invitation to the annual General Meeting 2024
19.03.2024 / 07:00 CET/CEST

Media release

PolyPeptide publishes invitation to the annual General Meeting 2024

Baar, 19 March 2024 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients,
published today the invitation to the third annual General Meeting which will take place on 10 April 2024 at the Chollerhalle in Zug.

At PolyPeptide Group AG's (the“Company”) third annual General Meeting which will take place on 10 April 2024 at the Chollerhalle in Zug (the“AGM 2024”), six current members of the Board of Directors will stand for re-election. Dorothee A. Deuring has decided not to stand for re-election as a member of the Board of Directors. The Board of Directors thanks Ms.
Deuring for her contribution. Peter Wilden is proposed for re-election as Chair of the Board of Directors, and Philippe Weber and Peter Wilden as members of the Remuneration and Nomination Committee.

The Board of Directors further proposes to the AGM 2024 the deletion of art. 25 para. 3 of the Company's Articles of Association relating to the aggregate compensation for consulting services to the Company provided by members of the Board of Directors. The proposed deletion shall eliminate any concerns regarding a possible impairment of the objectivity and independence of the members of the Board of Directors.

Further proposals include, among others, the re-election of the Statutory Auditors and the Independent Proxy as well as the approval of the maximum aggregate amount of compensation of the Board of Directors and Executive Committee. The shareholders will also be asked to approve the Management Report, Statutory Financial Statements and Consolidated Financial Statements, in each case, for the financial year 2023 as well as the Remuneration Report 2023 and the report on non-financial matters for the financial year 2023, both in separate consultative votes.

The invitation to the AGM 2024 with the detailed proposals and explanations can be found on the Company's website .


Contact

PolyPeptide Group AG
Michael Stäheli
Head of Investor Relations & Corporate Communications
...
T: +41 43 502 05 80


About PolyPeptide

PolyPeptide Group AG with its consolidated subsidiaries (“PolyPeptide”) is a focused Contract Development & Manufacturing Organization (CDMO) which specializes in the development and manufacturing of synthetic peptides and oligonucleotides used as active pharmaceutical
ingredients (API) or intermediates in therapeutic products. It also produces a range of generic peptides and peptides used in cosmetics. The Group mainly serves pharmaceutical and biotech companies. By supporting its customers, PolyPeptide contributes to the health of millions of
patients across the world. PolyPeptide provides its offering from pre-clinical through to commercial stages. Its active custom projects pipeline reflects the opportunities from novel drug therapies in development to fight both widespread and rare diseases. Established in 1952, PolyPeptide today runs a global network of six GMP-certified facilities in Europe, the U.S. and India.
PolyPeptide's shares (SIX: PPGN) are listed on SIX Swiss Exchange.

For more information, please visit polypeptide .

@PolyPeptide – follow us on LinkedIn


Disclaimer

This media release has been prepared by PolyPeptide Group AG and contains certain forward-looking statements that reflect the current views of management. Such statements are subject to known and unknown risks, uncertainties and other factors that may cause actual developments to differ materially from those expressed or implied in this release. PolyPeptide Group AG is providing the information in this release as of this date and, except as required by applicable laws or regulations, does not undertake any obligation to update any statements contained in it as a result of new information, future events or otherwise.

Additional features:

File: PolyPeptide_Publication of AGM 2024 Invitation_EN

End of Media Release

Language: English
Company: PolyPeptide Group
Neuhofstrasse 24
6340 Baar
Switzerland
Phone: +41435020580
E-mail: ...
Internet:
ISIN: CH1110760852
Valor: 111076085
Listed: SIX Swiss Exchange
EQS News ID: 1861385


End of News EQS News Service

MENAFN19032024004691010666ID1107994166


EQS Group

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.